Journal Mobile Options
Table of Contents
Vol. 98, No. 2, 2004
Issue release date: October 2004
Nephron Exp Nephrol 2004;98:e39–e44
(DOI:10.1159/000080254)

Molecular Aetiology of Primary Hyperoxaluria Type 1

Danpure C.J.
Department of Biology, University College London, London, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Primary hyperoxaluria type 1 (PH1) is a rare autosomal-recessive disorder, caused by a deficiency of the liver-specific intermediary-metabolic enzyme alanine:glyoxylate aminotransferase (AGT). AGT deficiency results in increased synthesis and excretion of the metabolic end-product oxalate and the deposition of insoluble calcium oxalate in the kidney and urinary tract. Numerous mutations and polymorphisms have been identified in the gene (AGXT) that encodes AGT, some of which interact synergistically to cause a variety of complex enzyme phenotypes, including AGT intraperoxisomal aggregation, accelerated degradation, and peroxisome-to-mitochondrion mistargeting. The latter is the single most common cause of PH1 and results from the functional interaction between a common Pro11Leu polymorphism and a disease-specific Gly170Arg mutation. The recent solution of the crystal structure of AGT has enabled the effects of several mutations and polymorphisms to be rationalised in terms of their likely effects on AGT conformation. Increased understanding of the molecular aetiology of PH1 has led to significant improvements in all aspects of the clinical management of the disorder, including diagnosis (by enzyme assay of percutaneous needle liver biopsies), prenatal diagnosis (by DNA analysis of chorionic villus samples) and treatment (by liver transplantation as a form of enzyme replacement therapy).



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Danpure CJ: Primary Hyperoxaluria; in Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds): The Molecular and Metabolic Bases of Inherited Disease. New York, McGraw-Hill, 2001, vol II, pp 3323–3367.
  2. Danpure CJ, Jennings PR: Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett 1986;201:20–24.
  3. Cooper PJ, Danpure CJ, Wise PJ, Guttridge KM: Immunocytochemical localization of human hepatic alanine: Glyoxylate aminotransferase in control subjects and patients with primary hyperoxaluria type 1. J Histochem Cytochem 1988;36:1285–1294.
  4. Danpure CJ, Purdue PE, Fryer P, Griffiths S, Allsop J, Lumb MJ, Guttridge KM, Jennings PR, Scheinman JI, Mauer SM, Davidson NO: Enzymological and mutational analysis of a complex primary hyperoxaluria type 1 phenotype involving alanine:glyoxylate aminotransferase peroxisome-to-mitochondrion mistargeting and intraperoxisomal aggregation. Am J Hum Genet 1993;53:417–432.
  5. Danpure CJ, Cooper PJ, Wise PJ, Jennings PR: An enzyme trafficking defect in two patients with primary hyperoxaluria type 1: Peroxisomal alanine/glyoxylate aminotransferase rerouted to mitochondria. J Cell Biol 1989;108:1345–1352.
  6. Purdue PE, Lumb MJ, Fox M, Griffo G, Hamon Benais C, Povey S, Danpure CJ: Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase. Genomics 1991;10:34–42.
  7. Takada Y, Kaneko N, Esumi H, Purdue PE, Danpure CJ: Human peroxisomal L-alanine:glyoxylate aminotransferase: Evolutionary loss of a mitochondrial targeting signal by point mutation of the initiation codon. Biochem J 1990;268:517–520.
  8. Motley A, Lumb MJ, Oatey PB, Jennings PR, De Zoysa PA, Wanders RJ, Tabak HF, Danpure CJ: Mammalian alanine:glyoxylate aminotransferase 1 is imported into peroxisomes via the PTS1 translocation pathway: Increased degeneracy and context specificity of the mammalian PTS1 motif and implications for the peroxisome-to-mitochondrion mistargeting of AGT in primary hyperoxaluria type 1. J Cell Biol 1995;131:95–109.
  9. Leiper JM, Oatey PB, Danpure CJ: Inhibition of alanine:glyoxylate aminotransferase dimerization is a pre-requisite for its peroxisome-to-mitochondrion mistargeting in primary hyperoxaluria type 1. J Cell Biol 1996;135:939–951.
  10. Zhang X, Roe SM, Hou Y, Bartlam M, Rao Z, Pearl LH, Danpure CJ: Crystal structure of alanine:glyoxylate aminotransferase and the relationship between genotype and enzymatic phenotype in primary hyperoxaluria type 1. J Mol Biol 2003;331:643–652.
  11. Purdue PE, Takada Y, Danpure CJ: Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1. J Cell Biol 1990;111:2341–2351.
  12. Lumb MJ, Danpure CJ: Functional synergism between the most common polymorphism in human alanine:glyoxylate aminotransferase and four of the most common disease-causing mutations. J Biol Chem 2000;275:36415–36422.
  13. von Schnakenburg C, Rumsby G: Primary hyperoxaluria type 1: A cluster of new mutations in exon 7 of the AGXT gene. J Med Genet 1997;34:489–492.
  14. Santana A, Salido E, Torres A, Shapiro LJ: Primary hyperoxaluria type 1 in the Canary Islands: A conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc Natl Acad Sci USA 2003;100:7277–7282.
  15. Pirulli D, Puzzer D, Ferri L, Crovella S, Amoroso A, Ferrettini C, Marangella M, Mazzola G, Florian F: Molecular analysis of hyperoxaluria type 1 in Italian patients reveals eight new mutations in the alanine: Glyoxylate aminotransferase gene. Hum Genet 1999;104:523–525.
  16. Purdue PE, Lumb MJ, Allsop J, Minatogawa Y, Danpure CJ: A glycine-to-glutamate substitution abolishes alanine: Glyoxylate aminotransferase catalytic activity in a subset of patients with primary hyperoxaluria type 1. Genomics 1992;13:215–218.
  17. Danpure CJ, Jennings PR: Further studies on the activity and subcellular distribution of alanine:glyoxylate aminotransferase in the livers of patients with primary hyperoxaluria type 1. Clin Sci 1988;75:315–322.
  18. Nishiyama K, Funai T, Katafuchi R, Hattori F, Onoyama K, Ichiyama A: Primary hyperoxaluria type I due to a point mutation of T to C in the coding region of the serine:pyruvate aminotransferase gene. Biochem Biophys Res Commun 1991;176:1093–1099.
  19. Nishiyama K, Funai T, Yokota S, Ichiyama A: ATP-dependent degradation of a mutant serine: pyruvate/alanine:glyoxylate aminotransferase in a primary hyperoxaluria type 1 case. J Cell Biol 1993;123:1237–1248.
  20. Danpure CJ, Jennings PR, Watts RW: Enzymological diagnosis of primary hyperoxaluria type 1 by measurement of hepatic alanine:glyoxylate aminotransferase activity. Lancet 1987;i:289–291.
  21. Danpure CJ, Rumsby G: Strategies for the prenatal diagnosis of primary hyperoxaluria type 1. Prenat Diagn 1996;16:587–598.
  22. Watts RW, Calne RY, Rolles K, Danpure CJ, Morgan SH, Mansell MA, Williams R, Purkiss P: Successful treatment of primary hyperoxaluria type I by combined hepatic and renal transplantation. Lancet 1987;ii:474–475.
  23. Danpure CJ: Scientific rationale for hepatorenal transplantation in primary hyperoxaluria type 1; in Touraine JL (ed): Transplantation and Clinical Immunology. Amsterdam, Excerpta Medica, 1991, vol 22, pp 91–98.
  24. Lumb MJ, Birdsey GM, Danpure CJ: Correction of an enzyme trafficking defect in hereditary kidney stone disease in vitro. Biochem J 2003;374:79–87.
  25. Danpure CJ, Rumsby G: Enzymology and molecular genetics of primary hyperoxaluria type 1: Consequences for clinical management; in Khan SR (ed): Calcium Oxalate in Biological Systems. Boca Raton, CRC Press, 1995, pp 189–205.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50